Alessandra Lugaresi

Summary

Affiliation: University of Chieti
Country: Italy

Publications

  1. pmc Improving patient-physician dialog: commentary on the results of the MS Choices survey
    Alessandra Lugaresi
    Department of Neuroscience and Imaging, University G D Annunzio, Chieti, Italy
    Patient Prefer Adherence 6:143-52. 2012
  2. pmc Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study
    Luisa Pastò
    Department of Neurology, University of Florence, Viale Morgagni 85, 50134, Florence, Italy
    BMC Neurol 12:165. 2012
  3. pmc Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
    Marta Giannini
    Department of Neurology, University of Florence, Florence, Italy
    BMC Neurol 12:124. 2012
  4. pmc Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
    Virginia Devonshire
    Department of Neurology, University of British Columbia, Vancouver, BC, Canada
    BMC Neurol 10:28. 2010
  5. doi RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence
    Alessandra Lugaresi
    Department of Neuroscience and Imaging, University G D Annunzio, c o Centro Sclerosi Multipla, Ospedale Clinicizzato SS Annunziata, Via dei Vestini 31, 66100 Chieti, Italy
    Expert Opin Drug Deliv 10:273-83. 2013
  6. pmc Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study
    Alessandra Lugaresi
    Department of Neuroscience and Imaging, University G, D Annunzio, Via dei Vestini 31, 66100 Chieti, Italy
    BMC Neurol 12:7. 2012
  7. pmc Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
    Valentina Durastanti
    Department of Neurological Sciences, University La Sapienza, Viale dell Universita, 30, 00185, Rome, Italy
    J Transl Med 9:42. 2011
  8. doi Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?
    Alessandra Lugaresi
    University Gabriele d Annunzio of Chieti Pescara, Ospedale Clinicizzato Santissima Annunziata, c o Centro Sclerosi multipla VII livello, corpo A, Department of Oncology and Neuroscience, Chieti, Italy
    Expert Opin Drug Deliv 6:995-1002. 2009
  9. doi A computational platform for MALDI-TOF mass spectrometry data: application to serum and plasma samples
    Dante Mantini
    Istituto Tecnologie Avanzate Biomediche ITAB, Fondazione G D Annunzio, Chieti, Italy
    J Proteomics 73:562-70. 2010
  10. doi Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery
    Damiana Pieragostino
    Centro Studi sull Invecchiamento Ce S I, Fondazione G d Annunizio, Chieti, Italy
    J Proteomics 73:579-92. 2010

Collaborators

  • Andrea Urbani
  • Piero Del Boccio
  • Dante Mantini
  • Helmut Butzkueven
  • Tjalf Ziemssen
  • Cavit Boz
  • Maura Pugliatti
  • Christoph Heesen
  • Claudia Goss
  • Stefano Sotgiu
  • Valentina Durastanti
  • Marco Onofrj
  • Claudio Gasperini
  • Marinella Clerico
  • Angelo Di Iorio
  • Carlo Pozzilli
  • Damiana Pieragostino
  • Maria Trojano
  • Luisa Pastò
  • Marta Giannini
  • Giovanna De Luca
  • Vilija G Jokubaitis
  • Erika Pietrolongo
  • Lorenzo Razzolini
  • Laura De Giglio
  • Maria Giovanna Marrosu
  • Damiano Paolicelli
  • Maria Pia Amato
  • Francesco Patti
  • Maria Rosaria Tola
  • Lucia Moiola
  • Angelo Ghezzi
  • Bahia Hakiki
  • Rocco Totaro
  • Elisa Piscolla
  • Claudio Solaro
  • Loredana La Mantia
  • Giancarlo Comi
  • Vittorio Martinelli
  • Emilio Portaccio
  • Carmine Di Ilio
  • Paolo Sacchetta
  • Virginia Devonshire
  • Domenico Gambi
  • Guillermo Izquierdo
  • Pierre Duquette
  • Freek Verheul
  • Jeannette Lechner-Scott
  • Marc Girard
  • Mark Slee
  • Jodi Haartsen
  • Carla Iarlori
  • François Grand'maison
  • Suzanne Hodgkinson
  • Cameron Shaw
  • Danny Liew
  • Daniele L A Spitaleri
  • Vivien Li
  • Tomas Kalincik
  • Raed Alroughani
  • Giorgio Giuliani
  • Michael Barnett
  • Maria Di Ioia
  • Monica Kleinefeld
  • Carla Tortorella
  • Diego Centonze
  • Luisa Pieroni
  • Davide Radice
  • Alessandra Solari
  • Paolo Confalonieri
  • Claudia Rossi
  • Diego Franciotta
  • Viviana Greco
  • Simona D'Aguanno
  • Andrea Giordano
  • Valeria Di Tommaso
  • Gianluigi Mancardi
  • Gian Luigi Mancardi
  • Michael Lang
  • Francesca Petrucci
  • Txomin Arbizu
  • Barry Singer
  • Bjorn Borre
  • Sara Tiberio
  • Giorgio Federici
  • Peter Cornelisse
  • Elisabetta Verdun di Cantogno
  • Claudio Feliciani
  • Marcella Reale
  • Pio Conti

Detail Information

Publications16

  1. pmc Improving patient-physician dialog: commentary on the results of the MS Choices survey
    Alessandra Lugaresi
    Department of Neuroscience and Imaging, University G D Annunzio, Chieti, Italy
    Patient Prefer Adherence 6:143-52. 2012
    ..Further, the possible implications of these findings for routine practice have been considered, and strategies that should be employed by MS physicians and nurses to help patients to adhere to their prescribed treatment are suggested...
  2. pmc Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study
    Luisa Pastò
    Department of Neurology, University of Florence, Viale Morgagni 85, 50134, Florence, Italy
    BMC Neurol 12:165. 2012
    ..The objective of this study was to assess the impact of epidural analgesia (EA) and caesarean delivery (CD) on the risk of post-partum relapses and disability in women with MS...
  3. pmc Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
    Marta Giannini
    Department of Neurology, University of Florence, Florence, Italy
    BMC Neurol 12:124. 2012
    ....
  4. pmc Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
    Virginia Devonshire
    Department of Neurology, University of British Columbia, Vancouver, BC, Canada
    BMC Neurol 10:28. 2010
    ..This study was performed to assess the suitability of a new electronic device for the subcutaneous (sc) administration of interferon (IFN) beta-1a, 44 mcg three times weekly, for relapsing MS...
  5. doi RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence
    Alessandra Lugaresi
    Department of Neuroscience and Imaging, University G D Annunzio, c o Centro Sclerosi Multipla, Ospedale Clinicizzato SS Annunziata, Via dei Vestini 31, 66100 Chieti, Italy
    Expert Opin Drug Deliv 10:273-83. 2013
    ..As injection-related problems are common barriers to adherence, autoinjectors have been developed to improve the ease and convenience of self-injection...
  6. pmc Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study
    Alessandra Lugaresi
    Department of Neuroscience and Imaging, University G, D Annunzio, Via dei Vestini 31, 66100 Chieti, Italy
    BMC Neurol 12:7. 2012
    ..We sought to assess short-term adherence to, and tolerability of, interferon (IFN) β-1a administered via electronic autoinjection device in patients with relapsing-remitting multiple sclerosis (RRMS)...
  7. pmc Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
    Valentina Durastanti
    Department of Neurological Sciences, University La Sapienza, Viale dell Universita, 30, 00185, Rome, Italy
    J Transl Med 9:42. 2011
    ..The aim of the study was to investigate the dynamic profile of neopterin and kyn/trp ratio in patients with relapsing remitting multiple sclerosis (RRMS) treated with two different doses of IFNβ-1a over a period of 24 months...
  8. doi Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?
    Alessandra Lugaresi
    University Gabriele d Annunzio of Chieti Pescara, Ospedale Clinicizzato Santissima Annunziata, c o Centro Sclerosi multipla VII livello, corpo A, Department of Oncology and Neuroscience, Chieti, Italy
    Expert Opin Drug Deliv 6:995-1002. 2009
    ..However, the benefits offered by treatment may be compromised by suboptimal levels of adherence to prescribed regimens...
  9. doi A computational platform for MALDI-TOF mass spectrometry data: application to serum and plasma samples
    Dante Mantini
    Istituto Tecnologie Avanzate Biomediche ITAB, Fondazione G D Annunzio, Chieti, Italy
    J Proteomics 73:562-70. 2010
    ..In this work, we propose an integrated software platform, MASCAP, intended for comparative biomarker detection from MALDI-TOF MS data...
  10. doi Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery
    Damiana Pieragostino
    Centro Studi sull Invecchiamento Ce S I, Fondazione G d Annunizio, Chieti, Italy
    J Proteomics 73:579-92. 2010
    ..Apolipoprotein A-IV and complement C3 protein fragments, transthyretin and the oxidized isoforms in different apolipoprotein species represent the major molecular features of such a degradation pattern...
  11. doi Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis
    Damiana Pieragostino
    Research Centre on Aging Ce S I, University G d Annunzio of Chieti Pescara, Chieti, Italy
    Proteomics 13:1002-9. 2013
    ..Moreover, we found low levels of free T4 in CSF of multiple sclerosis patients, suggestive of a potential role of these modifications in T4 transport into the brain...
  12. doi Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study
    Alessandra Lugaresi
    Department of Oncology and Neuroscience, University G D Annunzio, Chieti, Italy
    Clin Neuropharmacol 31:167-72. 2008
    ..This study investigated the satisfaction of patients with relapsing-remitting MS treated with IFN-beta-1a (Rebif) by the autoinjection system, Rebiject...
  13. pmc Fingolimod after natalizumab and the risk of short-term relapse
    Vilija G Jokubaitis
    From the Department of Medicine V G J, T K, H B, Melbourne Brain Centre RMH, The University of Melbourne Department of Neurology V G J, V L, T K, H B, Royal Melbourne Hospital, Australia Hospital Universitario Virgen Macarena G I, Seville, Spain Liverpool Hospital S H, New South Wales, Australia Amiri Hospital R A, Kuwait City, Kuwait John Hunter Hospital J L S, Newcastle, Australia MS Center A L, Department of Neuroscience and Imaging, University G D Annunzio, Chieti, Italy Hôpital Notre Dame P D, M G, Montreal, Canada Brain and Mind Research Institute M B, Sydney, Australia Neuro Rive Sud F G, Hopital Charles LeMoyne, Quebec, Canada Department of Basic Medical Sciences M T, Neuroscience and Sense Organs, University of Bari, Italy Flinders University and Medical Centre M S, Adelaide, Australia Ospedale di Macerata G G, Italy Geelong Hospital C S, Tel Aviv University
    Neurology 82:1204-11. 2014
    ....
  14. ncbi Interferon beta-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis
    Carla Iarlori
    Department of Oncology and Neuroscience, Neuroimmunology Unit, University G D Annunzio, Via dei Vestini, I 66013, Chieti, Italy
    J Neuroimmunol 123:170-9. 2002
    ..Logistic regression analysis shows that MCP-1 production is significantly modified by treatment. Further studies are needed to clarify the role of MCP-1 in MS...
  15. ncbi Cleavage of cystatin C is not associated with multiple sclerosis
    Piero Del Boccio
    Centro Studi Sull Invecchiamento, Fondazione G D Annunzio, Chieti, Italy
    Ann Neurol 62:201-4; discussion 205. 2007
    ..We conclude that the use of the 12.5 kDa product of cystatin C in cerebrospinal fluid might lead to a fallacious diagnosis of multiple sclerosis. Preanalytical validation procedure is mandatory for proteomics investigations...
  16. pmc Decision-making in multiple sclerosis consultations in Italy: third observer and patient assessments
    Erika Pietrolongo
    Department of Neuroscience and Imaging, University G d Annunzio of Chieti Pescara, Chieti, Italy
    PLoS ONE 8:e60721. 2013
    ..To assess decision-making in multiple sclerosis (MS) from third observer and patient perspectives...